SOS. Orozbaev

S. Orozbaev

*This is an algorithmically generated author record based on publicly available information.

S. Orozbaev has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Рак почки в ВОСТОЧНО-КАЗАХСТАНСКОЙ ОБЛАСТИ: компонентный анализ заболеваемости

    by Н.с. Игісін, С.с. Дьяков, Ж.б. Тельманова, И.о. Кудайбергенова, З.г. Хамидуллина, А.м. Джексенова, Ж.р. Ажетова, С.т. Орозбаев, Г.с. Игисинова, З.а. Билялова, et al.

    Введение. В мире каждый год диагностируется около 430 тысяч новых случаев рака почек (РП). РП является одним из наиболее важных видов рака, отчасти из-за того, что он продолжает налагать существенное экономическое бремя на систему здравоохранения. Изучение заболеваемости раком почек имеет большое научно-практическое значение в плане выявления факторов риска, мониторинга и оценки профилактических мероприятий и разработки новых методов диагностики и лечения. Цель исследования: оценить заболеваемость раком почек в Восточно-Казахстанской области с помощью компонентного анализа. Материалы и методы. В ретроспективном исследовании данных Министерства здравоохранения Республики Казахстан о новых случаях РП в Восточно-Казахстанской области, полученных из формы №7, использовались описательные и аналитические методы эпидемиологии. Для анализа динамики заболеваемости на основе количества случаев заболевания с 2010 по 2019 год был использован компонентный анализ. Результаты. За исследуемый период (2010–2019 годы) в Восточно-Казахстанской области (ВКО) было зарегистрировано 1 279 новых случая РП. Среднегодовая заболеваемость РП в ВКО составила 9,2±0,4 (95%ДИ=8,4-10,1) на 100 000 населения. Общий прирост заболеваемости у мужского населения составил +5,740/0000, а у женского населения +3,210/0000. Заболеваемость РП у оба пола увеличивается. Общее увеличение составило +4,420/0000и зависело от изменений в возрастной структуре населения (∑ΔA=+1,110/0000), риска заболеть (∑ΔR=+3,130/0000) и совокупного влияния возрастной структуры и риска заболеть (∑ΔAR=+0,180/0000). Согласно расчетам компонентного анализа, в 2019 году ожидалось 118 пациента. Вместо этого число пациентов увеличилось и составило 163. Таким образом, РП характеризуется увеличением случаев, в основном, из-за изменения риска заболеть (+42,0% от общего увеличения на +56,7%). Выводы. Наше исследование показывает, что прирост числа больных связан с факторами риска, с изменениями возрастной структуры населения области, которые связаны с изменением возрастного типа населения в сторону регрессивного. Улучшение политики в области здравоохранения и осведомленность о профилактике заболеваний могут сыграть важную роль в снижении бремени рака. Introduction. In the world, about 430 thousand new cases of kidney cancer (KC) are diagnosed every year. KC is one of the most important types of cancer, partly because it continues to impose a significant economic burden on the health care system. The study of the incidence of KC has great scientific and practical significance in terms of identifying risk factors, monitoring and evaluating preventive measures and developing new methods of diagnosis and treatment. The aim of the study is to evaluate the incidence of KC in East Kazakhstan region using component analysis. Material and research methods. In a retrospective study of the data of the Ministry of Health of the Republic of Kazakhstan on new cases of KC in the East Kazakhstan region, obtained from Form No.7, descriptive and analytical methods of epidemiology were used. To analyze the dynamics of incidence based on the number of cases from 2010 to 2019, a component analysis was used. Results. During the study period (2010-2019), 1,279 new cases of KC were registered in the East Kazakhstan region. The average annual incidence of KC in East Kazakhstan region was 9.2±0.4 (95%CI=8.4-10.1) per 100,000 population. The overall increase in incidence in the male population was +5.740/0000, and in the female population +3.210/0000. The incidence of KC in both sexes is increasing. The overall increase was +4.420/0000and depended on changes in the age structure of the population (∑ΔA=+1.110/0000), the risk of getting sick (∑ΔR=+3.130/0000) and the cumulative effect of the age structure and the risk of getting sick (∑ΔAR=+0.180/0000). According to the calculations of the component analysis, 118 patients were expected in 2019. Instead, the number of patients increased to 163. Thus, KC is characterized by an increase in cases, mainly due to a change in the risk of getting sick (+42.0% of the total increase by +56.7%). Conclusions.Our study shows that the increase in the number of patients is associated with risk factors, with changes in the age...

  • Open Access

    ВЛИЯНИЕ COVID-19 на показатели онкологической службы при раке молочной железы в Казахстане

    by Игісін Н.с., Тогузбаева А.я., Байбусунова А.ж., Тельманова Ж.б., Игисинова Г.с., Билялова З.а., Байбосынов Д.м., Ажетова Ж.р., Орозбаев С.т., Кулаев К.т., et al.

    Введение. По прогнозам Международного агентства по изучению рака в 2040 году прогнозируется около 3 миллионов новых случаев рака молочной железы (РМЖ) и ожидается, что около 1 миллиона женщин погибнут от данной патологии. Цель исследования: оценить влияние COVID-19 на показатели онкологической службы при РМЖ в Казахстане. Материалы и методы. Материалом исследования послужили данные Министерства здравоохранения Республики Казахстан – годовая форма №7 и №35, касающиеся РМЖ (МКБ 10 – С50) за 2011-2020. В качестве основного метода использовалось ретроспективное исследование с применением дескриптивных и аналитических методов медико-биологической статистики. Результаты. За 2011-2020 гг. в республике было зарегистрировано 42 376 новых случаев РМЖ и 12 914 смертей от данной патологии. Грубый показатель заболеваемости РМЖ составил 46,4±1,10/0000 (95% ДИ=44,3-48,5), показатель в динамике вырос с 40,8±0,70/0000(2011 г.) до 51,3±0,70/0000 в 2019 году и далее наблюдалось снижение до 44,2±0,70/0000 в 2020 году, различие было статистическим значимым (р<0,001). В динамике смертность от РМЖ снижалась значимому (р<0,001) с 16,1±0,40/0000(2009 г.) до 11,9±0,40/0000 в 2019 году и 11,5±0,40/0000в 2020 году, а среднегодовой грубый показатель составил 14,2±0,60/0000(95% ДИ=13,1-15,3). Удельный вес больных c I-II стадией вырос с 73,4% (2011 г.) до 86,9% в 2019 году, и снизился до 84,2% в 2020 году. Снизился удельный вес больных с III стадией (с 20,9% в 2011 г. до 8,4% в 2019 г. и до 10,0% в 2020 г.) и IV стадией (с 5,6% до 4,2% и 5,0%, соответственно) за изучаемые годы. Показатели морфологической верификации при РМЖ всегда были высокими и за изучаемые годы улучшились с 95,7% до 99,4%. Выводы. В результате анализа показателей онкологической службы при РМЖ установлены улучшение показателей морфологической верификации и ранней диагностики, снижение запущенности процесса и показателей смертности. Однако тенденции в 2011-2019 году значительно отличались от периода с 2011-2020 гг., что связано с влиянием пандемии COVID-19 на течение, учет и регистрацию РМЖ. Introduction. According to International Agency for Research on Cancer in 2040, about 3 million new cases of breast cancer (BC) are predicted and about 1 million women are expected to die from this pathology. The aim of the study to assess the impact of COVID-19 on the indicators of the oncological service for breast cancer in Kazakhstan. Material and research methods. The main method was a retrospective study using descriptive, analytical methods of biomedical statistics and data of the Ministry of Health of the Republic of Kazakhstan – form No.7 and 35 regarding BC (ICD 10 - C50) for 2011-2020. Results. For 2011-2020 42,376 new cases of BC and 12,914 deaths from this pathology were registered. The average annual crude incidence rate was 46.4±1.10/0000 (95%CI=44.3-48.5), and increased from 40.8±0.70/0000 (2011) to 51 .3±0.70/0000 in 2019 and then decrease to 44.2±0.70/0000 in 2020 (p<0.001). In dynamics, mortality rates tended to (p<0.001) decrease from 16.1±0.40/0000 (2009) to 11.9±0.40/0000 in 2019 and 11.5± 0.40/0000 in 2020, and the average annual crude mortality rate was 14.2±0.60/0000 (95%CI=13.1-15.3). Indicators of early diagnosis (stage I-II) improved from 73.4% (2011) to 86.9% in 2019, and decreased to 84.2% in 2020. Proportion of patients with stage III decreased (from 20.9% in 2011 to 8.4% in 2019 and to 10.0% in 2020) and stage IV (from 5.6% to 4.2% and 5.0%, respectively), i.e. neglect rates are declining. The indicators of morphological verification improved from 95.7% to 99.4% over the years. Conclusions. As a result of the analysis, an improvement in the indicators of morphological verification, early diagnosis, a decrease in the neglect and mortality rates were established. The trends in 2011-2019 differed significantly from the period from 2011-2020, which is due to the COVID-19 pandemic on the registration of BC. Кіріспе. Қатерлі ісік ауруын зерттеу жөніндегі халықаралық агенттіктің болжамына сәйкес, 2040 жылы сүт безі қатерлі ісігінің (СБҚІ) 3 миллионға жуық жаңа жағдайы болжанып, осы патологиядан 1 миллионға жуық әйел қайтыс болады деп күтілуде. Зерттеу мақсаты: Қазақстандағы сүт безі қатерлі ісігінің жанындағы онкологиялық қызметтің көрсеткіштеріне COVID-19...

  • EVALUATION OF TRENDS IN ONCOLOGICAL CARE FOR KIDNEY CANCER IN KAZAKHSTAN

    by S. Dyakov, Zh. Telmanova, Z. Bilalova, Zh. Azhetova, G. Igissinova, S. Orozbaev, I. Kudaibergenova, N. Igissinov

    Relevance: Worldwide, kidney cancer ranks sixth among the most frequently diagnosed cancers in men and 10th in women, accounting for 5% and 3% of all cancer diagnoses, respectively. In 2020, IARC reported 431,288 new cases and 179,368 deaths from kidney cancer worldwide. By 2040, they expect an increase of 40.4% in kidney cancer incidence (605,726 cases) and 59.4% in kidney cancer mortality (285,906 deaths). The study aimed to analyze some kidney cancer indicators (incidence, mortality, early diagnosis, neglect, morphological verification) to evaluate the oncological care in Kazakhstan in 2010-2019. Methods: A retrospective study using descriptive and analytical methods of biomedical statistics was used as the primary method. Results: From 2010 to 2019, 10,966 new cases of kidney cancer and 3,866 deaths from this pathology were registered in Kazakhstan. kidney cancer incidence increased from 5.6±0.2%⁰⁰⁰ (2010) to 6.7±0.2%⁰⁰⁰ in 2019 (p=0.000). Over time, mortality rates from kidney cancer tended to decrease from 2.6±0.1%⁰⁰⁰ (2010) to 1.9±0.1%⁰⁰⁰ in 2019 (p=0.000). The study reveals a trend: the indicators of early diagnosis (the share of patients with stage I-II) improved from 50.7% (2010) to 69.1% in 2019, and, accordingly, the balance of neglected patients decreased significantly with stage III (from 31.2% to 14.6%) and with stage IV (from 18.1% to 16.0%). Morphological verification indicators for KС improved by 44.7%, from 58.5% and 84.6%, respectively, in 2010 and 2019. Conclusion: The increase in kidney cancer incidence dictates further study of cause-and-effect relationships with risk factors for developing effective preventive measures and screening programs.


  • EVALUATION OF TRENDS IN ONCOLOGICAL CARE FOR KIDNEY CANCER IN KAZAKHSTAN

    by S. Dyakov, Zh. Telmanova, Z. Bilalova, Zh. Azhetova, G. Igissinova, S. Orozbaev, I. Kudaibergenova, N. Igissinov

    Relevance: Worldwide, kidney cancer (KC) ranks sixth among the most frequently diagnosed cancers in men and 10th in women, accounting for 5% and 3% of all cancer diagnoses, respectively. In 2020, IARC reported 431,288 new cases and 179,368 deaths from KC worldwide. By 2040, they expect an increase of 40.4% in KC incidence (605,726 cases) and 59.4% in KC mortality (285,906 deaths). The aim was to analyze some kidney cancer indicators (incidence, mortality, early diagnosis, neglect, morphological verification) to evaluate the oncological care in Kazakhstan in 2010-2019. 25. Ahmad O.E., Boschi-Pinto C., Lopez A.D., Murray C.J.L., Lozano R., Inoue M. Age standardization of rates: a new WHO standard. – GPE Discussion Paper Series: No.31. – EIP/GPE/EBD World Health Organization, 2001. https://cdn.who.int/media/docs/defaultsource/gho-documents/global-health-estimates/gpe_discussion_ paper_series_paper31_2001_age_standardization_rates.pdf. 21.11.2022 26. Мерков А.М., Поляков Л.Е. Санитарная статистика. – Ленинград: Медицина, 1974 г. – 384 с. [Merkov A.M., Polyakov L.E. Sanitarnaya statistika. – Leningrad: Medicina, 1974 g. – 384 s. (in Russ.)]. 27. Гланц C. Медико-биологическая статистика. Пер. с англ. — М.: Практика, 1998. – 459 с. 28. Расчет t-критерия Стьюдента при сравнении средних величин (онлайн калькулятор) [Raschet t-kriteriya St’yudenta pri sravnenii srednix velichin (onlajn kal’kulyator) (in Russ.)] // medstatistic. ru/calculators/averagestudent.html. 21.11.2022 29. Закон Республики Казахстан. О государственной статистике: утв. 19 марта 2010 года, № 257-IV [Zakon Respubliki Kazaxstan. O gosudarstvennoj statistike: utv. 19 marta 2010 goda, № 257-IV (in Russ.)] // http://adilet.zan.kz/rus/docs/Z100000257 30. WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. – 2013. . 21.11.2022. 31. Alkhateeb S.S., Alkhateeb J.M., Alrashidi E.A. Increasing trends in kidney cancer over the last 2 decades in Saudi Arabia // Saudi Med J. – 2015. – Vol. 36. – P. 698-703. https://doi.org/10.15537/smj.2015.6.10841 32. Arabsalmani M., Mohammadian-Hafshejani A., Ghoncheh M., Hadadian F., Towhidi F., Vafaee K., Salehiniya H. Incidence and mortality of kidney cancers, and human development index in Asia; a matter of concern // J. Nephropathol. – 2016. – Vol. 6. – P. 30-42. https://doi. org/10.15171/jnp.2017.06 33. Thorstenson A., Bergman M., Scherman-Plogell A.H., Hosseinnia S., Ljungberg B., Adolfsson J., Lundstam S. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005-2010: a population-based study from the national Swedish kidney cancer register // Scand. J. Urol. – 2014. – Vol. 48. – P. 231-238. https://doi.org/10.3109/21 681805.2013.864698 ОРГАНИЗАЦИЯ ЗДРАВООХРАНЕНИЯ Онкология и радиология Казахстана, №4 (66) 2022 9 Прозрачность исследования: Авторы несут полную ответственность за содержание данной статьи. Конфликт интересов: Авторы заявляют об отсутствии конфликта интересов. Финансирование: Авторы заявляют об отсутствии финансирования исследования. Вклад авторов: вклад в концепцию – Кудайбергенова И.О., Игисинов Н.С., Дьяков С.С.; научный дизайн – Билялова З.А., Игисинова Г.С., Дьяков С.С.; исполнение заявленного научного исследования – Орозбаев С.Т., Дьяков С.С.; интерпретация заявленного научного исследования – Ажетова Ж.Р., Дьяков С.С., Тельманова Ж.Б.; создание научной статьи – Дьяков С.С., Тельманова Ж.Б. Сведения об авторах: Дьяков Сергей Сергеевич – науч. сотр. ОО «Central Asian Institute for Medical Research», Астана, Республика Казахстан; аспирант ГУ «Кыргызской государственной медицинской академии им. Ахунбаева», Бишкек, Кыргызская Республика; врач лучевой диагностики в РГП на ПХВ «Национальном научном Центре Травматологии и Ортопедии им. Акад. Н.Д. Батпенова МЗ РК», Астана, Республика Казахстан, тел. +77024622269, e-mail: sergey_djakov@mail.ru, ID ORCID: https://orcid.org/0000-0001-7566-7094; Тельманова Жансая Бекмакановна – науч. сотр. ОО «Central Asian Institute for Medical Research», Астана, Республика Казахстан; науч. сотр. ОО «Eurasian Institute for Cancer Research», Бишкек, Кыргызская Республика; интерн 7-го курса факультета общей врачебной практики НАО «Медицинский университет Астана», Астана, Республика Казахстан, тел. +77075059398, e-mail: telmanova.zhansaya@gmail.com, ID ORCID: https://orcid.org/0000-0002-2364-6520; Билялова Зарина Ароновна – PhD, асс. проф., гл. науч. сотр. ОО «Central Asian Institute for Medical Research», Астана, Республика Казахстан; ст. науч. сотр. ОО «Eurasian Institute for Cancer...


  • THE IMPACT OF COVID-19 ON THE INCIDENCE OF RECTAL CANCER IN KAZAKHSTAN: RESULTS OF COMPONENT ANALYSIS

    by Zh. Telmanova, A. Axarin, A. Oralbek, S. Orozbaev, K. Kulayev, N. Shapambayev, Y. Kuandykov, Z. Bilalova, G. Igissinova, K. Rustemova, et al.

    Relevance: Every year, 732,210 new cases of RC are registered globally, with an incidence of 7.6 per 100,000. The COVID-19 pandemic has affected the screening, case detection, and referral of patients with an asymptomatic cancer diagnosis. The aim was to assess the trends in rectal cancer incidence in the entire population of Kazakhstan before and during the COVID pandemics. Methods: The data obtained from the Ministry of Healthcare of the Republic of Kazakhstan concerning RC (Form no. 7) was retrospectively studied by descriptive and analytical epidemiology methods. The component method was used to analyze RC incidence dynamics based on the number of cases from 2010 to 2020. Results: From 2010 to 2020, the risk of getting RC went down. An increase in incidence in 2010-2020 (+24.8%) was lower than in the preCOVID period of 2010-2019 (+37.2%). We found a sharp decrease in RC incidence from 2019 to 2020. The overall decrease was 0.89‰⁰⁰ due to changes in the age structure of the population (∑ΔA=+0.13‰⁰⁰), the risk of getting RC (∑ΔR=−1.02‰⁰⁰), and the combined impact of age structure and the risk of getting RC (∑ΔAR=−0.002‰⁰⁰). According to the component analysis, 1,662 patients with RC were expected in 2020; instead, only 1,471 cases were registered. Such a decline in cases was mainly due to a reduced risk of getting RC. Conclusions: The analysis of RC incidence trends in Kazakhstan shows a negative impact of COVID-19 on cancer care indicators and effectiveness. All oncological examinations were strengthened with the resumption of work after COVID restrictions. However, the number of screening visits remains lower than in previous years. Untimely diagnosis can increase the number of cases of late-stage CRC and an overall loss of years of life due to the lack of proper treatment. However, these forecasts can be mitigated by proper follow-up

  • THE IMPACT OF COVID-19 ON THE INCIDENCE OF RECTAL CANCER IN KAZAKHSTAN: RESULTS OF COMPONENT ANALYSIS

    by Zh. Telmanova, A. Axarin, A. Oralbek, S. Orozbaev, K. Kulayev, N. Shapambayev, Y. Kuandykov, Z. Bilalova, G. Igissinova, K. Rustemova, et al.

    Relevance: Every year, 732,210 new cases of RC are registered globally, with an incidence of 7.6 per 100,000. The COVID-19 pandemic has affected the screening, case detection, and referral of patients with an asymptomatic cancer diagnosis. The aim was to assess the trends in rectal cancer incidence in the entire population of Kazakhstan before and during the COVID pandemics. Methods: The data obtained from the Ministry of Healthcare of the Republic of Kazakhstan concerning RC (Form no. 7) was retrospectively studied by descriptive and analytical epidemiology methods. The component method was used to analyze RC incidence dynamics based on the number of cases from 2010 to 2020. Results: From 2010 to 2020, the risk of getting RC went down. An increase in incidence in 2010-2020 (+24.8%) was lower than in the preCOVID period of 2010-2019 (+37.2%). We found a sharp decrease in RC incidence from 2019 to 2020. The overall decrease was 0.89‰⁰⁰ due to changes in the age structure of the population (∑ΔA=+0.13‰⁰⁰), the risk of getting RC (∑ΔR=−1.02‰⁰⁰), and the combined impact of age structure and the risk of getting RC (∑ΔAR=−0.002‰⁰⁰). According to the component analysis, 1,662 patients with RC were expected in 2020; instead, only 1,471 cases were registered. Such a decline in cases was mainly due to a reduced risk of getting RC. Conclusions: The analysis of RC incidence trends in Kazakhstan shows a negative impact of COVID-19 on cancer care indicators and effectiveness. All oncological examinations were strengthened with the resumption of work after COVID restrictions. However, the number of screening visits remains lower than in previous years. Untimely diagnosis can increase the number of cases of late-stage CRC and an overall loss of years of life due to the lack of proper treatment. However, these forecasts can be mitigated by proper follow-up.